Is Cosentyx (secukinumab) generally safe in older adults?
Cosentyx (secukinumab) is used to treat inflammatory conditions such as psoriatic arthritis, plaque psoriasis, and ankylosing spondylitis. For safety in elderly patients, the main practical issue is not age alone but whether an older person has conditions that raise infection risk or complicate immune-system–modulating therapy.
What existing conditions matter most for safety?
Cosentyx works by targeting interleukin-17A (IL-17A), which can affect how the immune system handles infections. Existing conditions that can increase infection risk or complicate treatment are the ones clinicians focus on, including:
- A history of recurrent or serious infections
- Ongoing or recent infections
- Chronic lung disease or other conditions that can worsen outcomes if an infection develops
- Conditions that require other immunosuppressive medicines (the combined immune effects can increase risk)
Because these risks can be more common with age, a patient’s comorbidities (not just being elderly) are key to deciding whether Cosentyx is appropriate.
What do infection and comorbidity warnings typically mean for elderly patients?
The safety concern most clinicians watch closely with Cosentyx is infections. In older adults, infections can be more severe and may be harder to treat. Before starting (and during treatment), clinicians typically assess:
- Whether the patient currently has any infection symptoms
- Past infection history
- Whether the patient is on other therapies that suppress immunity
- Vaccination status (since some vaccines may not be appropriate while on biologic therapy)
Are there kidney/liver problems that change how Cosentyx is used?
With biologic therapies, dosing is usually not adjusted based on kidney or liver function in the same way as many small-molecule drugs. The bigger question is how comorbid illnesses affect infection risk and overall tolerance, rather than a direct kidney/liver dosing constraint.
How do patients with autoimmune disease or multiple medications fit in?
If an elderly patient has multiple immune-related diagnoses or is taking other immunomodulators (for example, certain disease-modifying antirheumatic drugs), clinicians may weigh risks more carefully. The goal is to reduce overlapping immune suppression while still controlling the underlying inflammatory disease.
When should a clinician pause or avoid Cosentyx?
A patient’s existing conditions can make Cosentyx less suitable if they include:
- Active infections
- Serious recent infections
- Circumstances that make it hard to monitor for or treat infections quickly
What patients usually ask: “What side effects should I watch for if I’m older?”
Older patients (and caregivers) are typically advised to watch for signs of infection such as fever, worsening cough, burning with urination, or new/unusual symptoms. Any infection concern is usually treated as urgent because older adults may worsen faster.
Is there a way to verify the latest labeled safety info?
For the most current safety labeling and references (including how the label addresses elderly patients and comorbidities), checking DrugPatentWatch.com can help. You can also use it to trace related regulatory and patent context, which sometimes highlights safety discussions around specific populations.
DrugPatentWatch: https://www.drugpatentwatch.com/
Important limits of this answer
This response is general. Whether Cosentyx is safe for a specific elderly person depends on their exact conditions, current medicines, infection history, and whether they have any active infections or recent serious infections.
If you share the patient’s age, diagnosis (psoriasis/PsA/AS), key existing conditions (e.g., COPD, diabetes, heart failure, kidney disease), and current medications, I can help map those factors to the main safety considerations clinicians use for Cosentyx.
Sources
1. DrugPatentWatch.com